EUVIMEDEUVIMED entdecken
Crossref

Necrostatin‐1 attenuates oral squamous cell carcinoma by modulating tumour immune response in mice

Lavanya Saravanan, Ashutosh Mahale, Vikram Gota, Piyush Khandelia, Onkar Prakash Kulkarni iD

Fundamental & Clinical Pharmacology · 2025

DOI: 10.1111/fcp.70008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2025. Verfasst von Lavanya Saravanan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Metabolic and Neuroscience Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad, India. Hauptthemen laut MEDLINE: Mouth Neoplasms, Imidazoles, Indoles, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Indian Council of Medical Research, Science and Engineering Research Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Necroptosis has been shown to play an important role in various pathologies, including pancreatic cancer (PDAC). However, its role in the progression of oral cancer (OSCC) remains unclear.

Objectives

To determine the expression of key necroptosis pathway markers in an OSCC mouse model and evaluate the therapeutic effect of a necroptosis inhibitor on the progression of OSCC. Methods and Results 4‐NQO‐induced OSCC in mice resembles very closely to human OSCC. The expression of RIPK‐1, RIPK‐3, MLKL and their respective phosphorylation was increased in OSCC tissues of cancer‐bearing mice. In the analysis of the necroptosis pathway in human OSCC with the TCGA database, we found similar overexpression of RIPK‐1 in human cancer, which correlated with the severity of cancer in terms of different cancer grades and stages. Pharmacological blockade of necroptosis with necrostatin‐1 (NEC‐1) reduced the progression and development of OSCC, characterized by reduced number and severity of tumour lesions, improved histology with reduced hyperplasia, dysplasia and invasive carcinoma. Immune profiling of blood, spleen and tumour tissues demonstrated suppressed expression of MDSCs (CD11b + Gr‐1 + ) and M2‐macrophages (CD11b + F4/80 + CD206 + ), while M1‐macrophages (CD11b + F4/80 + MHCII + ) were elevated in the treatment group. The ratio of M2/M1 was reduced in the treated group, suggesting the promotion of anti‐tumour immune response. Expression of Arg‐1, YM1/2, IL‐10 and TGF‐β was reduced in tumour tissues in the treated group.

Conclusion

In summary, blocking the necroptosis pathway alters the tumour microenvironment (TME) and inhibits the progression of OSCC. Targeting necroptosis could be an effective therapy for treating OSCC in a clinical setup.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mouth NeoplasmsImidazolesIndolesCarcinoma, Squamous CellAnimalsMiceNecroptosisReceptor-Interacting Protein Serine-Threonine KinasesHumansMice, Inbred C57BLDisease Models, AnimalMaleDisease ProgressionTumor Microenvironment

Stichwörter der Autor:innen

M1M2MDSCNecrostatin‐1OSCCRIPK‐1necroptosis

Substanzen

necrostatin-1ImidazolesIndolesReceptor-Interacting Protein Serine-Threonine Kinases

Autor:innen und Institutionen

  • Metabolic and Neuroscience Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Hyderabad, India.
  • Advance Centre for Treatment Research & Education in Cancer, Tata Memorial Centre (ACTREC), Navi Mumbai, Maharashtra, India.
  • Department of Biological Sciences, Birla Institute of Technology and Science-Pilani, Hyderabad, India.

ORCID-Profile: Onkar Prakash Kulkarni

Förderung

  • Indian Council of Medical Research
  • Science and Engineering Research Board

Zitieren

APA

Saravanan, L., Mahale, A., Gota, V., Khandelia, P., & Kulkarni, O. P. (2025). Necrostatin‐1 attenuates oral squamous cell carcinoma by modulating tumour immune response in mice. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.70008

Vancouver

Saravanan L, Mahale A, Gota V, Khandelia P, Kulkarni OP. Necrostatin‐1 attenuates oral squamous cell carcinoma by modulating tumour immune response in mice. Fundamental & Clinical Pharmacology. 2025. doi:10.1111/fcp.70008

BibTeX
@article{Saravanan2025,
  author = {Saravanan, Lavanya and Mahale, Ashutosh and Gota, Vikram and Khandelia, Piyush and Kulkarni, Onkar Prakash},
  title = {Necrostatin‐1 attenuates oral squamous cell carcinoma by modulating tumour immune response in mice},
  journal = {Fundamental & Clinical Pharmacology},
  year = {2025},
  doi = {10.1111/fcp.70008}
}
Kostenlos starten →